Cue Biopharma
CUE
Market cap $83.7M

1.39 USD

+0.23

19.83%

At close Oct 7, 4:00 PM EDT

After hours

1.33

-0.06

4.32%

1 day

19.83%

5 days

80.52%

1 month

144.29%

3 months

42.29%

6 months

-31.86%

Year to date

-50.00%

1 year

-31.86%

5 years

-81.97%

About: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Employees: 53

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

1,450% more call options, than puts

Call options by funds: $279K | Put options by funds: $18K

4% less funds holding

Funds holding: 77 [Q1] → 74 (-3) [Q2]

8.28% less ownership

Funds ownership: 36.66% [Q1] → 28.37% (-8.28%) [Q2]

14% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 22

32% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 22

45% less capital invested

Capital invested by funds: $31.3M [Q1] → $17.1M (-$14.1M) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2

44%

upside

Avg. target

$3

116%

upside

High target

$4

188%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Stifel Stephen Willey 33% 1-year accuracy 5 / 15 met price target	188%upside $4	Buy Maintained	20 Aug 2024
JMP Securities Reni Benjamin 32% 1-year accuracy 11 / 34 met price target	44%upside $2	Market Outperform Maintained	26 Jul 2024
Piper Sandler Edward Tenthoff 34% 1-year accuracy 13 / 38 met price target	116%upside $3	Overweight Maintained	26 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about CUE published over the past 30 days

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

BOSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced it will deliver an oral and a poster presentation on the company's Immuno-STAT™ clinical assets CUE-101 and CUE-102, representative of the CUE-100 series, at the Society for Immunotherapy of Cancer's 39th Annual Meeting (SITC 2024). The conference will be held in Houston, Texas, on November 6-10, 2024.

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the pricing of an underwritten public offering of (i) 11,564,401 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 2,891,100 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 12,435,599 shares of common stock and accompanying common stock warrants to purchase an aggregate of 3,108,900 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.50, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.499. The aggregate gross proceeds of the offering are expected to be approximately $12.0 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.50 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about September 30, 2024, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

Cue Biopharma Announces Proposed Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Announces Proposed Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.

Cue Biopharma Announces Proposed Public Offering

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the appointment of industry veteran Lucinda Warren as chief business officer (CBO).

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Cue Biopharma, Inc. (NASDAQ:CUE ) Q2 2024 Earnings Conference Call August 19, 2024 4:30 PM ET Company Participants Daniel Passeri - CEO Anish Suri - President & Chief Scientific Officer Matteo Levisetti - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel Ren Benjamin - Citizens JMP Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Edward Tenthoff - Piper Sandler Operator Good day, and welcome to the Cue Biopharma Second Quarter 2024 Earnings Call. All participants will be in a listen-only mode.

Cue Biopharma, Inc. (CUE) Q2 2024 Earnings Call Transcript

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

BOSTON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, provided a business and financial update for the second quarter 2024.

Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zacks Investment Research

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.29 per share a year ago.

Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates

Medical Moonshots: 3 Biotech Stocks Set to Skyrocket

Human life expectancy has doubled since the 1900s, mostly attributed to advancements in lifestyle, living standards and medicine. Thanks to biotech companies that produce transformative drugs and treatments, we now have the collective ability to combat diseases that used to bring entire nations down.

Medical Moonshots: 3 Biotech Stocks Set to Skyrocket

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.

Cue Biopharma to Present at the 20th Annual PEGS Boston Summit

See News Rankings

Charts implemented using Lightweight Charts™